Xinda weight loss drug has achieved the main endpoints of the latest three-phase study. It is planned to submit the marketing application for Masitide 9mg soon.

Shindabiology announces that the global first GCG/GLP-1 dual receptor agonist Marzitudipeptide has achieved the primary endpoint and all key secondary endpoints in the Phase III clinical study GLORY-2 in severely obese individuals with BMI30 in China. Data shows that compared to placebo, treatment with Marzitudipeptide 9mg achieved significant weight loss, especially with an average weight loss of 20.08% in the population with simple obesity. Currently, the approved dosage specifications for Marzitudipeptide are mainly 2mg, 4mg, and 6mg, for individuals with BMI28 or 24BMI28 and at least one obesity-related complication. Shindabiology plans to submit an application for the marketing approval of Marzitudipeptide 9mg for adult weight control to the National Medical Products Administration soon. Shindabiology stated that the development of Marzitudipeptide at different doses and administration regimens, the development of Marzitudipeptide 9mg is aimed at the weight loss needs of severely obese patients in China with a BMI greater than 30, especially those with a BMI of 32.5 or higher, a population that previously could only achieve effective weight management through weight loss surgery.